|
|
 |
|
Viewing report
|
|
|
|
Breast Cancer Therapeutics: How Innovation Is Shaping Future Therapies
Drug and Market Development Publishing, Jan 2006, Pages: 166
The Breast Cancer Therapeutics Report seeks to explore and systematically analyze both drug targets and associated therapeutics in current clinical development relating to breast cancer. Four major classes of breast cancer therapeutics are a particular focus - endocrine therapy, 'innovative' therapy, immunotherapy and chemotherapy. Several of the mainstream technologies utilized in breast cancer drug discovery are explored. Additionally, the therapeutic and market potential of each therapy type is investigated. This Report includes an up to date review of pipeline and market developments in the breast cancer therapeutics field.
Questions Answered
- Who is currently developing breast cancer therapeutics?
- What are the key drug targets that underlie such developments and which have the most therapeutic and commercial potential?
- How is breast cancer treatment changing?
- What are the relative merits of approved breast cancer therapeutics?
- What are the competitive advantages of new-generation breast cancer drugs?
- Where are the main challenges in breast cancer drug development?
- Are there any breast cancer patient sub-groups presently underserved by current and emerging therapies?
- Where are the opportunities relating to breast cancer drug development?
- What are the future prospects for breast cancer therapeutics?
Key Reasons to Purchase
- Determine what is new in breast cancer therapeutics by review of clinical developments in current pharmaceutical pipelines.
- Assess the therapeutic potential of breast cancer therapeutics by understanding the underlying drug targets and technology that that have facilitated drug development
- Assess the market potential of breast cancer therapeutics from maps of the current market landscape, an evaluation of the success of approved breast cancer therapeutics, and consideration of relevant future market projections.
- Get an up-to-date perspective on breast cancer drug development with a systematic review of each breast cancer therapy type
- Identify the key technological platforms currently utilized in breast cancer drug discovery.
- Look inside 20 companies involved in breast cancer drug discovery, including their product pipelines, financial standing, partnerships & alliances, and more
- Obtain a current industry snapshot of breast cancer drug discovery from a short survey conducted in parallel with the writing of this report.
- Gain insight into current challenges in breast cancer drug discovery through in-depth interviews with five industry experts.
Market Opportunities
There are approximately 50 breast cancer drugs in current development. Each of the four drug therapy categories identified in this report are witnessing significant developments. Market opportunities in this space include:
- Invest in basic research to establish a sound knowledge base on emerging breast cancer drug targets and their associated biology
- Develop model systems for clinical investigation of breast cancer to broaden applicability of breast cancer therapeutics and simplify clinical development.
- Develop technology platforms for development of targeted therapies with reduced side effects.
- Develop diagnostic tests for use with new therapies so that treatment regimes can be tailored for a specific patient.
- Investigate the possibility of cross-indications of breast cancer therapeutics to increase therapeutic value.
- Focus on breast cancer patient sub-groups that represent highest areas of unmet medical needs
About The Author
Dr Catherine M. Thomson has worked in medical and biological research for nineteen years. Research areas span cancer, neurodegenerative disease, and arthritis and rheumatism. A particular emphasis has been the development of visible molecular tags or indicator technology for medical research. Her PhD was obtained at the University of Wales College of Medicine, Cardiff, South Wales, UK and her first degree in Molecular Biology from Glasgow University, Scotland, UK. Over the past five years Dr Thomson has worked at, and for, the Center for Research and Education in Bioluminescence and Biotechnology (CREBB), Rutgers University, NJ, USA in roles of research, instruction and consulting. Dr Thomson currently works as a consultant and analyst for the pharmaceutical and biotechnology industries. Recently, Dr Thomson authored 'Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact,' and co-authored 'Fluorescent Proteins: Technologies, Applications, and Opportunities for Drug Discovery,' and 'A Guide to Green Fluorescent Protein: Applications in Cell Biology and Drug Discovery ,'
Product samples
EXECUTIVE SUMMARY
Customers who bought this item also bought
Stakeholder Insight: Hormonal Therapies in Breast Cancer
Cancer Drug Discoveries: What the Future Holds
Analysis of Prostate Cancer R&D: The Complete Guide
Targeted Cancer Therapies: Innovative Drugs And Their Impact On The Future Of Oncology
Stakeholder Insight: Adjunct Therapies in Breast Cancer
Analytical Tool - Current & Future Therapies for Colorectal Cancer
The Cancer Market Outlook to 2010
Breast Cancer Opinion Leader Forum
|
|
|
|
